STAT+: China tightens the reins on clinical trials, even as the U.S. looks for ways to replicate its rival’s speed

For years, U.S. scientists and biotech companies have watched warily as China has made strides onto the global stage, overtaking them in research spending, patent applications, and clinical trials. To many observers, it has been a sign that the U.S. needs to urgently modernize a lumbering clinical trial and regulatory system. But now, a key driver of China’s roaring biomedical engine — one that many researchers believe the U.S. should replicate — is being fine-tuned, and a system that was credit...